Retracted: Treatment with metallothionein prevents demyelination and axonal damage and increases oligodendrocyte precursors and tissue repair during experimental autoimmune encephalomyelitis

Media type: E-Article

Title: Retracted: Treatment with metallothionein prevents demyelination and axonal damage and increases oligodendrocyte precursors and tissue repair during experimental autoimmune encephalomyelitis

Contributor: Penkowa, Milena; Hidalgo, Juan

imprint: Wiley, 2003

Language: English

DOI: 10.1002/jnr.10615

ISSN: 0360-4012; 1097-4547

Keywords: Cellular and Molecular Neuroscience

Origination:

Footnote:

Description: Experimental autoimmune encephalomyelitis (EAE) is an animal model for the human demyelinating disease multiple sclerosis (MS). EAE and MS are characterized by significant inflammation, demyelination, neuroglial damage, and cell death. Metallothionein‐I and ‐II (MT‐I + II) are antiinflammatory and neuroprotective proteins that are expressed during EAE and MS. We have shown recently that exogenous administration of Zn‐MT‐II to Lewis rats with EAE significantly reduced clinical symptoms and the inflammatory response, oxidative stress, and apoptosis of the infiltrated central nervous system areas. We show for the first time that Zn‐MT‐II treatment during EAE significantly prevents demyelination and axonal damage and transection, and stimulates oligodendroglial regeneration from precursor cells, as well as the expression of the growth factors basic fibroblast growth factor (bFGF), transforming growth factor (TGF)β, neurotrophin‐3 (NT‐3), NT‐4/5, and nerve growth factor (NGF). These beneficial effects of Zn‐MT‐II treatment could not be attributable to its zinc content per se. The present results support further the use of Zn‐MT‐II as a safe and successful therapy for multiple sclerosis. © 2003 Wiley‐Liss, Inc.

Search in field:

Recently searched for: